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E-mail: jeffreybtigermd@gmail.comFig 1. Mid-dermal elastolysis: asymptomatic parchment-
like appearance of the skin on the trunk.REFERENCES
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immune reconstitution inflammatory
syndrome in an HIV-infected patient
To the Editor: The immune reconstitution inflamma-
tory syndrome (IRIS) encompasses a group of
disorders with different clinical manifestations
occurring in HIV-infected patients after starting
highly active antiretroviral therapy (HAART),
resulting from the restored ability of the immune
system to mount an antigen-specific inflammatory
response. Previous studies have demonstrated that
10% to 25% of HIV-positive patients starting on
antiretroviral therapy experience IRIS, and in more
than half of them cutaneous involvement represents
the first manifestation of the disease.1
A 32-year-old Caucasian man with a 13-year
history of HIV infection (CD4 cell count 269 cells/
mm3, plasma HIV RNA load [VL] 16,315 copies/mL)
started HAART in December 2012. Two months later
his CD4 cell count increased to 465 cells/mm3, and
the viral load was undetectable. At the same time,
the patient reported a progressive, asymptomatic,
erythematous, parchment-like appearance of the
skin on his trunk (Fig 1). He denied prolonged
ultraviolet light exposure.
Open access under CC BY-NC-ND license.A skin biopsy specimen showed a sparse
lymphohistiocytic infiltrate admixed with scattered,
multinucleated histiocytic giant cells arranged
between the collagen bundles in the mid dermis
(Fig 2, A). Focal elastophagocytosis was also noted.
Orcein staining highlighted a bandlike loss of elastic
fibers in the mid dermis (Fig 2, B). A diagnosis of
mid-dermal elastolysis was made. Four months
later the patient experienced gastrointestinal
symptoms associated with perianal fistulae. A
diagnosis of Crohn’s disease was confirmed
by radiologic, endoscopic, and histopathological
examination.
Mid-dermal elastolysis is a rare condition charac-
terized by localized, bandlike loss of elastic fibers in
the mid dermis.2 It presents clinically with variably
large areas of fine wrinkling, tiny perifollicular
papules, or both. The pathogenesis is unclear.
Several cases seem to be related to ultraviolet radi-
ation, whereas in others immunologic mechanisms
may be involved. The association with different
autoimmune disorders and the elevated antinuclear
antibody found in some patients with mid-dermal
elastolysis have supported the hypothesis of an
autoimmune origin.2
To our knowledge, mid-dermal elastolysis in the
course of HIV infection has been reported only
once.3 In contrast to our patient, the onset of skin
lesions was unrelated to treatment, and an
association with actinic damage was suggested as
Fig 2. Mid-dermal elastolysis. A, Detail of multinucleated
giant cells in the mid dermis with occasional elastopha-
gocytosis. B, Bandlike loss of elastic fibers in the mid
dermis. (A, Hematoxylin-eosin stain; original magnifica-
tion:3200.) (B, Orcein stain; original magnification:340.)
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Letters e135the cause of the skin disease. In our patient,
skin manifestations of mid-dermal elastolysis
appeared at the same time of the immune restoration
after HAART, thus suggesting that they may be
etiologically related. Indeed, our case fulfills
diagnostic criteria of IRIS, namely: temporal
association between initiation of HAART and
development of symptoms, evidence of immune
restoration with virologic and immunologic
response, and clinical symptoms consistent with an
inflammatory process.1 The subsequent occurrence
of Crohn’s disease may support the intriguing
hypothesis of a multiorgan autoimmune IRIS
phenomenon. In fact, IRIS-induced tissue inflamma-
tion may result in an increase in local inflammatory
cytokines and recognition of viral and/or
self-antigens by the infiltrating T cells.4 The
inflammatory environment induced by IRIS and the
loss of immune self-tolerance to tissue-associated
antigens may lead to increased susceptibility to
develop local and/or systemic pathological
autoimmune conditions.5 This mechanism could
support the hypothesis that mid-dermal elastolysis
is an autoimmune process against elastic fibers.
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Clinicopathologic lessons in distinguishing
cicatricial alopecia: 7 Cases of lichen
planopilaris misdiagnosed as discoid lupus
To the Editor: Cicatricial alopecia represents a
complex set of scarring hair loss conditions. They
present challenges in initial diagnostic evaluation,
histopathological analysis, and long-term manage-
ment.1,2 Clinically, the hallmark of cicatricial
alopecia is obliteration of follicular ostia, reflecting
follicular destruction, secondary to inflammation.
The common cicatricial alopecias marked by
lymphocytic inflammation include discoid lupus
erythematosus (DLE), lichen planopilaris (LPP),
frontal fibrosing alopecia (a clinical variant of LPP),
and central centrifugal cicatricial alopecia. Because
both clinical and histologic features of lymphocytic
scarring alopecia overlap, distinguishing between
them can be difficult, especially the distinction
between DLE and LPP.3,4
Seven patients with scarring alopecia were
referred by dermatologists to 1 of 2 specialty clinics
in Boston ( focused on connective tissue diseases or
alopecia). All patients were diagnosed with
DLE based on clinical and histopathologic findings,
